Many patients ask:

“If my lab report says the fungus is sensitive to the antifungal drug, why is my condition not improving quickly?”

This is a very reasonable question.

The short answer is: fungi are biologically adaptable, and we are still learning how they adjust inside the lung.

Recent research involving scientists working with the National Aspergillosis Centre (NAC), including work led by Dr. Weaver and colleagues, is helping us understand this better.

You can read the scientific abstract here:
🔗 https://pubmed.ncbi.nlm.nih.gov/41673015/

---

1️⃣ What Does “Sensitive” Mean in the Lab?

When Aspergillus is tested against a drug (such as itraconazole or voriconazole), laboratories measure the minimum inhibitory concentration (MIC).

This tells us the drug level needed to stop fungal growth in a controlled lab setting.

If the MIC is low, the fungus is labelled “sensitive.”

But the laboratory environment is very different from a lung cavity.

---

2️⃣ The Lung Is Not a Uniform Environment

In chronic pulmonary aspergillosis (CPA), the fungus often lives inside:

• Cavities

• Scarred lung tissue

• Fungal balls

• Thick mucus

Within these areas there can be:

• Low oxygen

• Variable iron levels

• Uneven drug penetration

• Different levels of immune activity

This means that different parts of the same infection can behave differently at the same time.

---

3️⃣ New Research: Fungi Have Fine-Tuned Control Systems

Recent work from researchers collaborating with NAC, including Prof. Bowyer’s group, has shown that Aspergillus contains additional regulatory elements in its genome called long non-coding RNAs (lncRNAs).

These do not make proteins.
Instead, they help fine-tune how nearby genes behave under stress.

In laboratory studies, some of these regulatory elements appear to influence how the fungus responds to antifungal drugs — even when there is no classic resistance mutation.

This suggests:

• Aspergillus can adjust how strongly certain pathways (like ergosterol production) are activated.

• These adjustments may help the fungus survive stressful conditions.

• This survival does not always show up as “resistance” in standard lab testing.

This does not mean the drug does not work.
It means the biological response can be more subtle and layered than we previously understood.

---

4️⃣ Resistance vs Tolerance — An Important Difference

Resistance

• Caused by stable genetic mutations.

• The drug becomes much less effective.

• MIC levels rise clearly.

Tolerance

• The fungus survives but grows slowly.

• MIC may still appear “sensitive.”

• The fungus adapts temporarily to stress conditions.

The new regulatory findings may help explain tolerance — not necessarily resistance.

---

5️⃣ Why This Matters for CPA

CPA is a chronic condition.

Inside lung cavities:

• Drug levels may vary.

• Oxygen levels fluctuate.

• Stress signals are ongoing.

This environment encourages survival strategies.

Research like the Weaver study helps us understand why:

• Treatment response may be gradual.

• Cultures can be intermittently positive.

• Stability may be the goal rather than rapid clearance.

---

6️⃣ How Could This Research Help in the Future?

It is important to be realistic: this research is still at an early stage.

However, understanding these regulatory systems opens new possibilities.

Instead of thinking only about killing the fungus directly, future approaches might aim to:

• Weaken its survival responses.

• Reduce its ability to enter protective stress states.

• Make existing antifungal drugs work more effectively.

For example, research in fungal biology has already shown that interfering with certain stress-buffering pathways can increase azole effectiveness in laboratory models.

In the longer term, this type of work could lead to:

🔹 Better Diagnostics

Tests that detect not only resistance mutations, but also stress-adapted or tolerance states.

🔹 More Personalised Treatment

Identifying strains that rely heavily on stress adaptation and adjusting therapy accordingly.

🔹 Combination Strategies

Using antifungal drugs together with agents that reduce fungal stress tolerance, helping prevent persistence.

These ideas are still under investigation, and no lncRNA-based treatments exist yet.
But this research expands the way scientists think about fungal treatment.

---

7️⃣ Encouraging News

The important message is this:

NAC is actively involved in research that improves our understanding of how Aspergillus behaves under treatment.

This work:

• Does not suggest current treatments are ineffective.

• Does not mean patients are resistant.

• Does highlight why long-term management can be complex.

• Represents steady progress in understanding fungal biology.

Understanding these regulatory systems is a step toward:

• Better diagnostics

• More personalised treatment strategies

• Improved long-term outcomes

---

A Reassuring Perspective

If progress feels slow, it is not because you or your clinicians have failed.

It reflects the adaptable survival biology of a fungus living in a complex lung environment.

And importantly, NAC and its research partners — including groups such as Dr. Weaver’s — are working to understand this biology in order to improve care.

Path: Start » Research » Why Can Aspergillus Infection Be Hard to Clear — Even When Tests Say It’s “Sensitive”?